ClinicalTrials.gg
CompletedNCT01396057COMRADE-BUpdated Aug 7, 2014Results posted

Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Branch Retinal Vein Occlusion (BRVO)

A Phase 3 interventional study of Ranibizumab and Dexamethasone Implant in Visual Impairment, Macular Edema and Branch Retinal Vein Occlusion, sponsored by Novartis Pharmaceuticals. Completed at 66 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-08-07.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
244
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing ranibizumab in Vision Disorders — none open to participants now, none under way, none of them phase 3. Ranibizumab · Vision Disorders.

Enrollment
9th of 26
244 · median 178
Started
2011
with 3 others
Phase 3
14 of 26
none open now
Registered
10th of 26
by date
Lead sponsor
20 of 26
Novartis Pharmaceuticals

Among the 26 studies testing ranibizumab in Vision Disorders, this one is the 9th largest by enrollment, is one of 4 that started in 2011, is one of 14 in phase 3, and was the 10th registered.

Vision Disorders

361 studies on the registry are indexed under Vision Disorders; 85 are open to participants now.

Browse Vision Disorders studies →

Open to participants now

None of the 26 studies testing ranibizumab in Vision Disorders is open now. The open studies under Vision Disorders, anywhere →

About ranibizumab

Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 46 Vision Disorders studies recruiting now, 21 (46%) set no upper age limit and 16 (35%) stop at 75 or younger; 18 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 26 studies testing ranibizumab in Vision Disorders as a file.
02

Study summary

This clinical trial is designed to compare ranibizumab in comparison with Dexamethasone implant after 6 months of treatment. In the study arm Ranibizumab will be given monthly in a pro re nata scheme whereas the comparator Dexamethasone implant is given once at Month 0 with sham injections PRN afterwards.

03

Conditions studied

  • Visual Impairment
  • Macular Edema
  • Branch Retinal Vein Occlusion

Keywords

  • Visual impairment
  • macular edema
  • branch retinal vein occlusion
  • Dexamethasone implant
  • Ranibizumab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients diagnosed with visual impairment due to macular edema following BRVO
  • Diagnosis of BRVO at maximum 6 months prior to Screening
  • BCVA using ETDRS charts of 20/40 to 20/400 in the study eye

Exclusion criteria

Exclusion Criteria:

  • Media clarity, pupillary dilation and patient cooperation not sufficient for adequate fundus photographs
  • Central retinal thickness (CRT) \< 250 µm in the study eye
  • Prior episode of RVO in the study eye
  • Active formation of new vessels in the study eye
  • Anti-VEGF-treatment in the study or the fellow eye 3 months prior to Baseline
  • IOP ≥ 30mmHg or uncontrolled glaucoma; patients may be re-screened after 1 month if they have undergone glaucoma treatment
  • Improvement of > 10 letters on BCVA between Screening and Baseline

Other protocol-defined inclusion/exclusion criteria may apply

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
244 participants (actual)

Study arms

  • Experimental
    Ranibizumab

    Injections consisted of 0.5 mg/0.05 ml solution to be injected intravitreally

    Drug: Ranibizumab

  • Sham comparator
    Dexamethasone

    Intravitreal implant as per commercial label (700 μg Dexamethasone; long acting release (LAR) over 6 months

    Other: Dexamethasone Implant · Other: Sham injection

Interventions

  • Injections consisted of 0.5 mg/0.05 ml solution to be injected intravitreally. Ranibizumab was formulated as a sterile solution aseptically filled in a sterile glass vial. It was suitable for single use only and the content of the vial was not allowed to be split

  • OtherDexamethasone Implant

    Comparator Ozurdex® (dexamethasone) was formulated as a rod shaped implant to be inserted into the eye by an applicator. The implant as well as the respective applicator were suitable for single use only.

  • OtherSham injection

    Sham injection: Empty sterile syringes were provided so that masking could be maintained. Either empty syringes in the case of sham injections or pre-filled syringes in the case of ranibizumab injections were visible to the patient in the room of study drug administration

06

What researchers measure

Primary outcomes

  1. Mean Average Best Corrected Visual Acuity (BCVA) Change From Month 1 Through Month 6 to Baseline

    the average of the changes in BCVA (letters) from baseline to any post-baseline visit, i.e. the mean of six differences to baseline for the six post-baseline visits at month 1 to 6

    Time frame: Baseline, month 6

Secondary outcomes

  1. Mean BCVA Change From Baseline to Endpoints Month 1 to Month 6

    The analysis was performed by an analysis of covariance (ANCOVA) model with average change in BCVA (letters) from Visit 1 through Visit 6 as dependent variable, and with the factors center, treatment and covariate baseline BCVA as predictors

    Time frame: Baseline, month 6

  2. Percentage of Patients Gaining / Losing ≥ 15 / 10 / 5 Letters After 6 Month Treatment

    BCVA score was based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. An ETDRS visual acuity score of 85 is approximately 20/20. An increased score indicates improvement in acuity. This outcome assessed the percentage of participants who gained 15, 10 or 5 more letters of visual acuity at month 6 as compared with baseline

    Time frame: Baseline, 6 month

  3. Time to Achieve a Significant Improvement ≥ 15 Letters

    The time was analyzed by the Kaplan-Maier-Method, adjusting the calculation for dropouts

    Time frame: Baseline, month 6

  4. Change Over Time in BCVA

    The analysis was performed by an analysis of covariance (ANCOVA) model with average change in BCVA (letters) from Visit 1 through Visit 6 as dependent variable, and with the factors center, treatment and covariate baseline BCVA as predictors

    Time frame: baseline, month 6

  5. Change Over Time of the Central Retinal Thickness (CRT)

    Retinal thickness was measured using Optical Coherence Tomography (OCT). The images were reviewed by a central reading center to ensure a standardized evaluation

    Time frame: Baseline, month 6

  6. Changes in the Quality of Life According to the National Eye Institute Visual Function Questionnaire (NEI-VFQ 25) Questionnaires

    The VFQ-25 composite and subscale scores range from 0 to 100, a higher score indicating better functioning. The 12 subscales in the VFQ-25 are general health, general vision, ocular pain, near activities, distance activities, social function, mental health, role difficulties, dependency, driving, color vision, and peripheral vision. The scores on the subscales were added together for a total score, which ranged from 0 to 100. A higher score indicated improvement in quality of life due to vision function.

    Time frame: Baseline, month 6

  7. Changes in the Quality of Life According to the Short Form (36) Health Survey (SF-36)Questionnaires

    SF-36 summary measures are norm-based scores with mean = 50 and SD = 10. Higher scores indicate better health

    Time frame: Baseline, month 6

  8. Changes in the Quality of Life According to Euro Quality of Life (EQ-5D) Questionnaires

    The EQ-5D visual analog scale ranges from 0 to 100, 0 representing the worst and 100 the best imaginable health state.

    Time frame: Baseline, month 6

  9. Rate of the Internal Ocular Pressure (IOP)

    The proportion of patients with ≥ 10% increase in IOP compared to baseline at any post-baseline visit.

    Time frame: Baseline, month 6

07

Results

Posted Jul 16, 2014

Participant flow

Participant flow — Overall Study
MilestoneRanibizumabDexamethasone
Started126118
Completed115100
Not completed1118
Withdrew: Adverse event26
Withdrew: Unsatisfactory therapeutic effect26
Withdrew: Protocol deviation44
Withdrew: Consent withdrawn32

Outcome measures

PrimaryMean Average Best Corrected Visual Acuity (BCVA) Change From Month 1 Through Month 6 to Baseline

the average of the changes in BCVA (letters) from baseline to any post-baseline visit, i.e. the mean of six differences to baseline for the six post-baseline visits at month 1 to 6

Time frame:
Baseline, month 6
Reported as:
Mean · Letters
Mean Average Best Corrected Visual Acuity (BCVA) Change From Month 1 Through Month 6 to Baseline
LettersRanibizumabDexamethasone
Mean Average Best Corrected Visual Acuity (BCVA) Change From Month 1 Through Month 6 to Baseline14.9 ± 9.910.1 ± 9.5
SecondaryMean BCVA Change From Baseline to Endpoints Month 1 to Month 6

The analysis was performed by an analysis of covariance (ANCOVA) model with average change in BCVA (letters) from Visit 1 through Visit 6 as dependent variable, and with the factors center, treatment and covariate baseline BCVA as predictors

Time frame:
Baseline, month 6
Reported as:
Least squares mean · Letters (EDTRS)
Mean BCVA Change From Baseline to Endpoints Month 1 to Month 6
Letters (EDTRS)RanibizumabDexamethasone
Mean BCVA Change From Baseline to Endpoints Month 1 to Month 616.18 (14.04 to 18.32)8.10 (5.79 to 10.40)
SecondaryPercentage of Patients Gaining / Losing ≥ 15 / 10 / 5 Letters After 6 Month Treatment

BCVA score was based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. An ETDRS visual acuity score of 85 is approximately 20/20. An increased score indicates improvement in acuity. This outcome assessed the percentage of participants who gained 15, 10 or 5 more letters of visual acuity at month 6 as compared with baseline

Time frame:
Baseline, 6 month
Reported as:
Number · Participants
Percentage of Patients Gaining / Losing ≥ 15 / 10 / 5 Letters After 6 Month Treatment
ParticipantsRanibizumabDexamethasone
Gain≥15 letters7744
Loss of ≥15 letters06
Gain ≥10 letters9763
Loss of ≥10 letters28
Gain ≥5 letters10876
Loss of ≥5 letters414
SecondaryTime to Achieve a Significant Improvement ≥ 15 Letters

The time was analyzed by the Kaplan-Maier-Method, adjusting the calculation for dropouts

Time frame:
Baseline, month 6
Reported as:
Median · Time to event (Days)
Time to Achieve a Significant Improvement ≥ 15 Letters
Time to event (Days)RanibizumabDexamethasone
Time to Achieve a Significant Improvement ≥ 15 Letters63 (56 to 84)64 (59 to 126)
SecondaryChange Over Time in BCVA

The analysis was performed by an analysis of covariance (ANCOVA) model with average change in BCVA (letters) from Visit 1 through Visit 6 as dependent variable, and with the factors center, treatment and covariate baseline BCVA as predictors

Time frame:
baseline, month 6
Reported as:
Least squares mean · Letters
Change Over Time in BCVA
LettersRanibizumabDexamethasone
Month 110.35 (8.53 to 12.17)10.44 (8.48 to 12.40)
Month 213.84 (12.04 to 15.64)12.62 (10.69 to 14.56)
Month 315.52 (13.44 to 17.59)9.16 (6.92 to 11.39)
Month 414.39 (12.38 to 16.41)8.59 (6.42 to 10.76)
Month 514.65 (12.52 to 16.78)9.08 (6.79 to 11.37)
Month 616.18 (14.04 to 18.32)8.10 (5.79 to 10.40)
SecondaryChange Over Time of the Central Retinal Thickness (CRT)

Retinal thickness was measured using Optical Coherence Tomography (OCT). The images were reviewed by a central reading center to ensure a standardized evaluation

Time frame:
Baseline, month 6
Reported as:
Mean · µm
Change Over Time of the Central Retinal Thickness (CRT)
µmRanibizumabDexamethasone
Change Over Time of the Central Retinal Thickness (CRT)-230.6 ± 169.3-112.3 ± 172.1
SecondaryChanges in the Quality of Life According to the National Eye Institute Visual Function Questionnaire (NEI-VFQ 25) Questionnaires

The VFQ-25 composite and subscale scores range from 0 to 100, a higher score indicating better functioning. The 12 subscales in the VFQ-25 are general health, general vision, ocular pain, near activities, distance activities, social function, mental health, role difficulties, dependency, driving, color vision, and peripheral vision. The scores on the subscales were added together for a total score, which ranged from 0 to 100. A higher score indicated improvement in quality of life due to vision function.

Time frame:
Baseline, month 6
Reported as:
Mean · Score on a scale
Changes in the Quality of Life According to the National Eye Institute Visual Function Questionnaire (NEI-VFQ 25) Questionnaires
Score on a scaleRanibizumabDexamethasone
Changes in the Quality of Life According to the National Eye Institute Visual Function Questionnaire (NEI-VFQ 25) Questionnaires7.2 ± 10.22.8 ± 12.6
SecondaryChanges in the Quality of Life According to the Short Form (36) Health Survey (SF-36)Questionnaires

SF-36 summary measures are norm-based scores with mean = 50 and SD = 10. Higher scores indicate better health

Time frame:
Baseline, month 6
Reported as:
Mean · Units on a scale
Changes in the Quality of Life According to the Short Form (36) Health Survey (SF-36)Questionnaires
Units on a scaleRanibizumabDexamethasone
SF-36 physical component (n=121,114)-1.1 ± 5.7-0.4 ± 5.7
SF-36 mental component (n=121,114)3.3 ± 9.20.2 ± 9.6
SecondaryChanges in the Quality of Life According to Euro Quality of Life (EQ-5D) Questionnaires

The EQ-5D visual analog scale ranges from 0 to 100, 0 representing the worst and 100 the best imaginable health state.

Time frame:
Baseline, month 6
Reported as:
Mean · Units on a scale
Changes in the Quality of Life According to Euro Quality of Life (EQ-5D) Questionnaires
Units on a scaleRanibizumabDexamethasone
Changes in the Quality of Life According to Euro Quality of Life (EQ-5D) Questionnaires0.7 ± 15.2-2.4 ± 15.4
SecondaryRate of the Internal Ocular Pressure (IOP)

The proportion of patients with ≥ 10% increase in IOP compared to baseline at any post-baseline visit.

Time frame:
Baseline, month 6
Reported as:
Number · Participants
Rate of the Internal Ocular Pressure (IOP)
ParticipantsRanibizumabDexamethasone
Rate of the Internal Ocular Pressure (IOP)79106

Adverse events

Non-serious events are listed at a 2.5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ranibizumab—7/126 (5.6%)71/126 (56.3%)
Dexamethasone—9/118 (7.6%)89/118 (75.4%)
Most frequent serious events
Showing 10 of 33
Most frequent serious events
EventRanibizumabDexamethasone
CONJUNCTIVITIS (Study eye)Eye disorders0/1261/118
OCULAR HYPERTENSION (Study eye)Eye disorders0/1261/118
ABDOMINAL HERNIAGastrointestinal disorders0/1261/118
INGUINAL HERNIAGastrointestinal disorders0/1261/118
RECTAL HAEMORRHAGEGastrointestinal disorders0/1261/118
UMBILICAL HERNIAGastrointestinal disorders0/1261/118
APPENDICITISInfections and infestations0/1261/118
BRONCHITISInfections and infestations0/1261/118
CELLULITIS (Study eye)Infections and infestations0/1261/118
FOOT FRACTUREInjury, poisoning and procedural complications0/1261/118
Most frequent other events
Showing 10 of 39
Most frequent other events
EventRanibizumabDexamethasone
OCULAR HYPERAEMIA (Study eye)Eye disorders16/12621/118
NASOPHARYNGITISInfections and infestations20/12621/118
INTRAOCULAR PRESSURE INCREASEDInvestigations3/12619/118
INTRAOCULAR PRESSURE INCREASED (Study eye)Investigations2/12617/118
CONJUNCTIVAL HAEMORRHAGE (Study eye)Eye disorders12/12614/118
EYE PAIN (Study eye)Eye disorders9/12613/118
HEADACHENervous system disorders13/12611/118
OCULAR DISCOMFORT (Study eye)Eye disorders2/1268/118
FOREIGN BODY SENSATION IN EYES (Study eye)Eye disorders8/1264/118
MACULAR OEDEMA (Study eye)Eye disorders4/1267/118

Baseline characteristics

Age, Continuous
Age, Continuous(Years)RanibizumabDexamethasoneTotal
Mean65.7 ± 10.965.6 ± 10.065.6 ± 10.5
Sex: Female, Male
Sex: Female, Male(Participants)RanibizumabDexamethasoneTotal
Female7657133
Male5061111
08

Study locations

66 sites
  • Novartis Investigative Site
    Praha 10, 100 34, Czech Republic
  • Novartis Investigative Site
    Augsburg, 85155, Germany
  • Novartis Investigative Site
    Bad Rothenfelde, 49215, Germany
  • Novartis Investigative Site
    Berlin, 10713, Germany
  • Novartis Investigative Site
    Berlin, 13353, Germany
  • Novartis Investigative Site
    Bochum, 44791, Germany
  • Novartis Investigative Site
    Bonn, 53127, Germany
  • Novartis Investigative Site
    Bremen, 28209, Germany
  • Novartis Investigative Site
    Chemnitz, 09116, Germany
  • Novartis Investigative Site
    Darmstadt, 64298, Germany
  • Novartis Investigative Site
    Dresden, 01257, Germany
  • Novartis Investigative Site
    Duesseldorf, 40225, Germany
  • Novartis Investigative Site
    Düsseldorf, 40212, Germany
  • Novartis Investigative Site
    Frankfurt, 60318, Germany
  • Novartis Investigative Site
    Freiburg i. Br, 79106, Germany
  • Novartis Investigative Site
    Glauchau, 08371, Germany
  • Novartis Investigative Site
    Göttingen, 37075, Germany
  • Novartis Investigative Site
    Hagen, 58097, Germany
  • Novartis Investigative Site
    Halle, 06114, Germany
  • Novartis Investigative Site
    Hamburg, 20246, Germany
  • Novartis Investigative Site
    Hamburg, 22417, Germany
  • Novartis Investigative Site
    Homburg, 66421, Germany
  • Novartis Investigative Site
    Ingolstadt, 85049, Germany
  • Novartis Investigative Site
    Karlsruhe, 76133, Germany
  • Novartis Investigative Site
    Karlsruhe, 76199, Germany
  • Novartis Investigative Site
    Kiel, 24105, Germany
  • Novartis Investigative Site
    Koeln, 50935, Germany
  • Novartis Investigative Site
    Leipzig, 04103, Germany
  • Novartis Investigative Site
    Ludwigshafen, 67063, Germany
  • Novartis Investigative Site
    Marburg, 35039, Germany
  • Novartis Investigative Site
    Minden, 32427, Germany
  • Novartis Investigative Site
    Muelheim, 45468, Germany
  • Novartis Investigative Site
    Muenster, 48145, Germany
  • Novartis Investigative Site
    Muenster, 48149, Germany
  • Novartis Investigative Site
    Munich, 80336, Germany
  • Novartis Investigative Site
    München, 81675, Germany
  • Novartis Investigative Site
    Recklinghausen, 45657, Germany
  • Novartis Investigative Site
    Regensburg, 93042, Germany
  • Novartis Investigative Site
    Sulzbach, 66280, Germany
  • Novartis Investigative Site
    Tübingen, 72076, Germany
  • Novartis Investigative Site
    Ulm, 89075, Germany
  • Novartis Investigative Site
    Wolfsburg, 38442, Germany
  • Novartis Investigative Site
    Würzburg, 97080, Germany
  • Novartis Investigative Site
    Budapest, 1083, Hungary
  • Novartis Investigative Site
    Debrecen, 4004, Hungary
  • Novartis Investigative Site
    Szeged, H-6720, Hungary
  • Novartis Investigative Site
    Bydgoszcz, Poland
  • Novartis Investigative Site
    Bytom, 41-902, Poland
  • Novartis Investigative Site
    Birmingham, B152WB, United Kingdom
  • Novartis Investigative Site
    Birmingham, B18 7QU, United Kingdom
  • Novartis Investigative Site
    Bradford, BD9 6RJ, United Kingdom
  • Novartis Investigative Site
    Cheshire, CW14QJ, United Kingdom
  • Novartis Investigative Site
    Colchester, CO3 3NB, United Kingdom
  • Novartis Investigative Site
    Derby, DE22 3NE, United Kingdom
  • Novartis Investigative Site
    Gloucester, GL1 3NN, United Kingdom
  • Novartis Investigative Site
    Guildford, Surrey, GU2 5XX, United Kingdom
  • Novartis Investigative Site
    Kent, CT1 3NG, United Kingdom
  • Novartis Investigative Site
    Leeds, LS9 7TF, United Kingdom
  • Novartis Investigative Site
    London, SE1 7EH, United Kingdom
  • Novartis Investigative Site
    Manchester, M13 9WH, United Kingdom
  • Novartis Investigative Site
    Middlesborough, TS4 3BW, United Kingdom
  • Novartis Investigative Site
    Nottingham, NG7 2UH, United Kingdom
  • Novartis Investigative Site
    Portsmouth, PO6 3LY, United Kingdom
  • Novartis Investigative Site
    Rugby, CV22 5PX, United Kingdom
  • Novartis Investigative Site
    Westcliff-on-Sea, SS0 0RY, United Kingdom
  • Novartis Investigative Site
    York, YO31 8HE, United Kingdom
09

References and documents

Publications

  • Shalchi Z, Mahroo O, Bunce C, Mitry D. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion. Cochrane Database Syst Rev. 2020 Jul 7;7(7):CD009510. doi: 10.1002/14651858.CD009510.pub3. PubMed 32633861 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2011, a primary completion of Jun 2013 and a completion of Jun 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2014, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2011
First posted
Jul 18, 2011
Start
Jul 2011
Primary completionActual
Jun 2013
CompletionActual
Jun 2013
Results first posted
Jul 16, 2014
Last update
Aug 7, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01396057
Responsible party
Sponsor
First posted
Jul 18, 2011
Start date
Jul 2011
Primary completion
Jun 2013
Completion
Jun 2013
Results posted
Jul 16, 2014
Last update
Aug 7, 2014

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranibizumab

Start the discussion